QIAGEN N.V. (QGEN) is a publicly traded Healthcare sector company. As of May 21, 2026, QGEN trades at $35.09 with a market cap of $6.97B and a P/E ratio of 0.00. QGEN moved +2.42% today. Year to date, QGEN is -24.52%; over the trailing twelve months it is -17.82%. Its 52-week range spans $32.53 to $57.82. Analyst consensus is buy with an average price target of $42.35. Rallies surfaces QGEN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Qiagen debuts QIA Agent and integrates NVIDIA BioNeMo for AI drug discovery: Qiagen launched QIA Agent globally, an AI-powered digital assistant that streamlines experiment planning, product selection, technical guidance and ordering via a conversational interface. Qiagen’s Digital Insights division will integrate NVIDIA’s accelerated computing and BioNeMo platform to enhance AI-driven drug discovery from target identification to biomarker research.
| Metric | Value |
|---|---|
| Price | $35.09 |
| Market Cap | $6.97B |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 1.26% |
| 52-Week High | $57.82 |
| 52-Week Low | $32.53 |
| Volume | 1.44M |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
12 analysts cover QGEN: 0 strong buy, 6 buy, 6 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $42.35.